UCLA researchers receive $3 million to develop AI for aggressive prostate cancer detection

NewsGuard 100/100 Score

Researchers at the UCLA Health Jonsson Comprehensive Cancer Center have received a five-year, $3 million grant from the National Cancer Institute to identify novel cancer biomarkers and develop AI that can detect and predict aggressive prostate cancer to help avoid unnecessary treatments and their associated negative side effects.

Despite recent advancements, prostate cancer remains a common and serious health issue for men, and current methods of screening and risk assessment can often lead to overdiagnosis and overtreatment. About 90% of people diagnosed with prostate cancer receive treatment, even though up to 60% of them could be candidates for active surveillance.

The project will be led by Corey Arnold, professor of radiology and pathology and laboratory medicine, and includes Paul Boutros, professor of human genetics and urology; Dr. Leonard Marks, professor of urology; Dr. Anthony Sisk, assistant professor of pathology and laboratory medicine; and Dr. Steven Raman, professor of radiology. The team will collaborate with investigators at Washington University in St. Louis to integrate magnetic resonance imaging, digital histology images, genetic information, and biomarkers in a computational model that can more precisely capture a patient's current cancer state and forecast outcomes.

We expect this approach to be able to provide more accurate information about the nature of the cancer, helping doctors to distinguish between aggressive and less threatening forms. It will also allow for more personalized and targeted treatment plans, reducing unnecessary interventions and their associated negative effects on patients' quality of life."

Corey Arnold, director of the UCLA Computational Diagnostics team

The project complements ongoing prostate cancer-focused grants in radiology led by faculty members Kyung Sung and Holden Wu.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New AI tool 'TORCH' successfully identifies cancer origins in unknown primary cases